We evaluated initiation of a GLP-1 receptor agonist and the risk of the composite endpoint of all SUDs by subgroups defined according to age, sex, race, BMI categories, HbA 1c levels, and type of GLP-1 receptor agonist
This article is for informational purposes only and doesnt constitute veterinary advice
The peptide program is detailed on the advanced peptide therapy page
Jing-Jing Cardona Sep 27, 2024 4 min read Updated: Feb 5 Semaglutide and tirzepatide have become prominent in weight loss and diabetes management due to their proven effectiveness
In studies of GLP-1 RAs, used as a monotherapy or in combination with other glucose-lowering therapies, mean HbA 1c changes from baseline ranged from 0.2% to 1.9% ( 2.2 to 20.9 mmol/mol) (Fig
Institutional review boards, biosafety committees, and chemical safety offices may have specific protocols for procuring and storing investigational compounds